

**THE UNIVERSITY OF BRITISH COLUMBIA**  
**Curriculum Vitae for Faculty Members**

Date: July 26, 2016

Initials:

1. **SURNAME:** Steidl **FIRST NAME:** Christian  
**MIDDLE NAME(S):** Georg
2. **DEPARTMENT/SCHOOL:** (a) Pathology & Laboratory Medicine (UBC)  
(b) Department of Lymphoid Cancer Research (BCCA)
3. **FACULTY:** Medicine
4. **PRESENT RANK:** **SINCE:**  
a) Associate Professor July 2016  
b) Senior Scientist July 2016

5. **POST-SECONDARY EDUCATION**

University or Institution	Degree	Subject Area	Dates
Universitat Witten / Herdecke, Germany	Ph.D.	Pathology	Feb 1998 – June 2003
University of Muenster Medical School, Germany	M.D.	Medicine	Oct 1995 – Dec 2001

(b) **Special Professional Qualifications**

(c) **Continuing Education /Training**

University / Institution	Department	Rank or Title	Dates
University of Goettingen, Germany	Hematology & Oncology	Resident	April 2002 – April 2006
British Columbia Cancer Agency, Canada	Pathology	Research Fellow	May 2006 – Sep 2011

6. **EMPLOYMENT RECORD**

(a) *Prior to coming to UBC*

University, Company or Organization	Rank or Title	Dates
University of Goettingen, Department of Hematology & Oncology, Division of Hematological Cytogenetics (Germany)	Physician Scientist	2002 - 2006

(b) *At UBC*

Rank or Title	Dates
Assistant Professor, University of British Columbia, Department of Pathology & Laboratory Medicine	October 2011 – June 2016

Scientist, British Columbia Cancer Agency, Department of Lymphoid Cancer Research	October 2011 – June 2016
Deputy Department Head, British Columbia Cancer Agency, Department of Lymphoid Cancer Research	April 2014 – June 2016
Research Director, Centre for Lymphoid Cancer, British Columbia Cancer Agency	January 2016 – June 2016
Associate Professor, University of British Columbia, Department of Pathology & Laboratory Medicine	July 2016 – Present
Senior Scientist, British Columbia Cancer Agency, Department of Lymphoid Cancer Research	July 2016 – Present
Department Head, British Columbia Cancer Agency, Department of Lymphoid Cancer Research	July 2016 – Present

(c) *Date of granting of tenure at U.B.C.:*

## 7. LEAVES OF ABSENCE

University, Company or Organization at which Leave was taken	Type of Leave	Dates

## 8. TEACHING

(a) *Areas of special interest and accomplishments*

1. Pathogenesis of lymphoid cancers
2. Blood and Lymphatics
3. Biomarker in Medicine
4. Tumor microenvironment

(b) *Courses Taught at UBC*

Session	Course Number	Scheduled Hours	Class Size	Hours Taught			
				Lectures	Tutorials	Labs	Other
2012-2013	Path 500A	20	23	1.5	1	NA	NA
2012-2013	Path 500B	20	23	2	18	NA	NA
2012-2013	MedG 421	30	38	1.5	NA	NA	NA
2012-2013	ONCO 502	34.5	17	1.5	NA	NA	NA
2013-2014	Path 500B	20	12	2	20	NA	NA
2013-2014	MedG 421	30	32	1.5	NA	NA	NA
2013-2014	ONCO 502	34.5	14	1.5	NA	NA	NA
2013-2014	GenomicPath	4.5	46	1.0	NA	NA	NA
2014-2015	Path 502	20	20	2	20	NA	NA
2014-2015	MedG 421	30	30	1.5	NA	NA	NA
2014-2015	ONCO 502	34.5	14	1.5	NA	NA	NA
2014-2015	GenomicPath	4.5	22	1.5	NA	NA	NA
2015-2016	ONCO 502	34.5	19	1.5	NA	NA	NA
2015-2016	Path 502	20	19	2	20	NA	NA

(c) *Graduate Students Supervised*

Student Name	Program Type	Year		Supervisory Role (supervisor, co-supervisor, committee member)
		Start	Finish	
Jon Obst	Master's	2013	---	Committee Chair
David Twa	MD/PhD	2012	---	Primary Supervisor
Fong Chun Chan	Doctorate	2012	---	Primary Supervisor
Jithendra Gunawardana	Doctorate	2010	2015	Primary Supervisor
Robert Kridel	Doctorate	2010	---	Committee member
Ada Leung	Doctorate	2010	---	Committee member
Rachel Huang	Doctorate	2011	---	Committee member
Scott Brown	Doctorate	2014	---	Committee member
Fong Chun Chan	Master's	2010	2012	Co-Supervisor
Tang Lee	Master's	2007	2009	Co-supervisor
Aimee Laporte	Master's	2013	---	Committee member
Amanda Davison	Master's	2014	---	Committee Chair
Arash Samiei	Master's	2014	---	Committee Chair
Linda (Xining) Yang	Master's	2013	---	Committee member
Arezoo Mohajeri	Master's	2014	---	Committee member
Stephen Yu	Master's	2014	---	Committee member
Rebecca Johnston	Master's	2014	---	Primary Supervisor
Abigail Baticados	Master's	2014	---	Primary Supervisor
Lauren Chong	Master's	2014	2016	Primary Supervisor
Gunjan Kumar	Master's	2015	---	Committee member
Olga Kutovaya	Post-Doctorate	2014	---	Primary Supervisor
Shannon Healy	Post-Doctorate	2013	---	Primary Supervisor
Anja Mottok	Post-Doctorate	2013	---	Primary Supervisor
David Scott	Post-Doctorate	2010	2014	Co-Supervisor
Greg Hapgood	Post-Doctorate	2014		Co-Supervisor
Dasiuke Ennishi	Post-Doctorate	2011	---	Primary Supervisor
Elena Vigano	Post-Doctorate	2016	---	Primary Supervisor

(d) *Continuing Education Activities*

1. Teaching assistance for the UBC Pathology Residency Program, 2007: Introduction into genome-wide analysis tools
2. BCCA Medical Oncology Residency Training Program 2009-2013: Annual reviews and seminar presentations of American Society of Hematology (ASH) Meeting Highlights ("Best of ASH")
3. Seminars for Centre for Translational and Applied Genomics (CTAG) and Centre for Lymphoid Cancer

(e) *Visiting Lecturer (indicate university/organization and dates)*(f) *Other*

1. Associate Faculty Member CIHR/MSFHR Bioinformatics Training Program (since November 2011)
2. Associate Faculty Member Interdisciplinary Oncology Program (since September 2012)
3. Course Organizer PATH 502: General Principles of Pathology (since 2014)

Attended seminars

1. Faculty of Graduate Studies workshop, Vancouver General Hospital, Vancouver, BC, Canada, May 30, 2012
2. 2015 Executive Development Seminar for Aspiring Leaders, Association of American Medical Colleges, Washington, DC, April 30 – May 2, 2015

(g) *Invited Lectures*

- a) “Molecular Assessment of the Tumour Microenvironment in Classical Hodgkin lymphoma”, Banff Pathology Course 2015, Molecular Diagnostics in Daily Practice, Banff, AB, August 28, 2015
- b) “Acquired immune privilege in B cell lymphomas”, Cancer Center Grand Rounds, Keck School of Medicine, University of Southern California (USC), Los Angeles, CA, May 5, 2015
- c) “Acquired immune privilege in B cell lymphomas”, Seminar talk, New York University, New York, NY, March 26, 2015
- d) “Acquired immune privilege in B cell lymphomas”, Seminar series at Deeley Research Centre, British Columbia Cancer Agency, Victoria, BC, October 6, 2014
- e) Next generation sequencing of B cell lymphomas. Teaching: UBC Hematopathology Rounds, April 22 2014
- f) Emerging hallmarks of B cell lymphomas – The next generation. BC Cancer Agency Research Seminar Series, April 14, 2014,
- g) “Next generation sequencing in lymphoid cancers – what have we learned so far?” Seminar series, University Medical Center Groningen, Netherlands, October 10, 2013
- h) Lymphoma Genomics: Diagnostic Precision Tools for Guiding Treatments: Canadian Society for Pharmaceutical Sciences Annual Symposium 2013, Vancouver, BC, June 2013
- i) Next-generation Sequencing of Lymphoid Cancers: From Discovery to Clinical Translation, American Society of Hematology (ASH) meeting, Atlanta, GA, December 2012
- j) Lymphoma Genomics – Discovery for Better Treatments, BCCA conference, 2012 Annual Cancer Conference of the BC Cancer Agency, Vancouver 2012
- k) Impact of NGS on Molecular Hematopathology, Association for Molecular Pathology Meeting 2012, Long Beach, CA, October 2012
- l) Next generation sequencing of B cell lymphomas: what have we learned so far? Seattle Blood Club, Seattle, WA, May 2012
- m) The Microenvironment in Hodgkin Lymphoma – Pathogenic and Clinical Relevance. The 2011 European Multidisciplinary Cancer Congress, Stockholm, Sweden, September 2011
- n) Genomics in Hodgkin lymphoma: All roads lead to the tumour microenvironment, BC Cancer Agency’s Vancouver Research Centre seminar series, July 2011
- o) A molecular approach to Hodgkin Lymphoma: Understanding treatment failure. 1<sup>st</sup> International Symposium on Childhood Adolescent and Young Adult Hodgkin Lymphoma (ISCAY AHL), Arlington, VA, May 2011
- p) Molecular characterization of Hodgkin lymphoma: Genome-wide approaches for biomarker discovery, 2010 Annual Cancer Conference of the BC Cancer Agency, Vancouver 2010
- q) Gene expression profiling in Hodgkin Lymphoma: The HRS cells or the microenvironment? 7th International Symposium on Hodgkin Lymphoma, Cologne 2007, Germany

9. **SCHOLARLY AND PROFESSIONAL ACTIVITIES**

(a) *Areas of special interest and accomplishments*

1. **Discovery of novel gene fusions and coding sequence mutations in Hodgkin lymphoma, primary mediastinal B cell lymphoma and mantle cell lymphoma using massively parallel sequencing (ongoing research at the BC Cancer Agency since January 2009)** Dr. Steidl is lead author on a scientific publication in *Nature* describing the MHC class II transactivator *CIITA* as a recurrent gene fusion partner in lymphoid cancers (*Nature*. 2011 Mar 17;471(7338):377-81). This world's first discovery defines a new subset of lymphomas characterized by these rearrangements leading to immune privilege of the malignant cells in Hodgkin lymphoma and primary mediastinal B cell lymphoma. A patent for the use of *CIITA* rearrangement detection as a diagnostic and prognostic clinical tool has been filed (US Provisional patent application, invention # 09-038). Dr Steidl is also the senior author on a next generation sequencing study of primary mediastinal B cell lymphoma describing first-of-its-kind somatic mutations of protein tyrosine phosphatase *PTPN1* (*Nature Genetics* 2014, in press). Dr Steidl wrote a literature review on the molecular pathogenesis of primary mediastinal B cell lymphoma (*Blood*. 2011. Sep 8;118(10):2659-69). Furthermore, Dr. Steidl is senior author on a scientific publication in *Blood* describing for the first time frequency and functional impact of somatic *NOTCH1* mutations in mantle cell lymphoma using massively parallel whole transcriptome sequencing (*Blood*. 2012. Mar 1;119(9):1963-71).

2. **Characterization of novel biomarkers for outcome prediction in Hodgkin lymphoma (ongoing research at the BC Cancer Agency since May 2006)** Dr Steidl is lead author on a scientific publication in the *New England Journal of Medicine* describing a correlation of tumor-associated macrophages with progression-free and disease-specific survival in classical Hodgkin lymphoma. (*N Engl J Med*. 2010 Mar 11;362(10):875-85). Furthermore, Dr Steidl identified recurrent chromosomal imbalances and gene expression profiles of Hodgkin Reed-Sternberg to be associated with treatment outcome (*Blood*. 2010 Jul 22;116(3):418-27 and *Blood*, Nov 2009; 114: 268). These studies identified novel biomarkers for outcome prediction and risk-stratification in Hodgkin lymphoma. Dr Steidl holds a patent for the use of gene expression profiling for prediction of overall survival in advanced stage classic Hodgkin lymphoma (US Provisional Patent application # 61569116). Dr Steidl wrote a literature review on the molecular pathogenesis of Hodgkin Lymphoma with emphasis on biomarkers (*Journal of Clinical Oncology*. 2011 May 10;29(14):1812-26) and a book chapter on Genomics in Hodgkin lymphoma (*Hodgkin Lymphoma*, ISBN 978-3-642-12779-3, pages 357-365, Springer Berlin Heidelberg 2011).

3. **Investigations on the prognostic impact of classical cytogenetics in myelodysplastic syndromes (ongoing research at the University of Goettingen since 2002 and now as member of the MDS International Working Group on Prognosis in Myelodysplasia)** Dr Steidl has significantly contributed to a refinement of prognostic scoring systems in myelodysplastic syndromes and is senior author on a scientific publication in *Blood* investigating the prognostic impact of karyotypic changes in a large international patient cohort (*Blood*. 2007 Dec 15;110(13):4385-95). He is lead and second author, respectively, on publications comparing the prognostic impact of poor-risk cytogenetics with other prognostic markers (*Clinical Leukemia*. 2007 Dec; 1(6):353-356) and *Journal of Clinical Oncology*. 2011 May 20;29(15):1963-70) and was involved in the development of a new comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS (*Journal of Clinical Oncology*. 2012. Mar 10;30(8):820-9). Dr. Steidl is member of the MDS International Working Group on Prognosis in Myelodysplasia and has written two book chapters on cytogenetics in MDS (*MDS and acute myeloid leukemia: a biological and therapeutic continuum*. UNI-MED Verlag AG, Bremen Germany, 2007; *The Myelodysplastic Syndromes*. ISBN 978-94-007-0439-8, Springer, Germany, 2011).

4. **Characterization of a single nucleotide polymorphism in acute myeloid leukemia (University of Goettingen, 2002-2007)**

The applicant is first authors on a scientific publication in the *Journal of Clinical Investigations* characterizing a single nucleotide polymorphism that alters long-range regulation of the *SPI1* gene in acute myeloid leukemia (*J Clin Invest*. 2007 Sep;117(9):2611-20).

(b) *Research or equivalent grants (indicate under COMP whether grants were obtained competitively (C) or non-competitively (NC))*

<b>Granting Agency</b>	<b>Title of Proposal</b>	<b>COMP</b>	<b>Total Amount Funded (CAD)</b>	<b>Year</b>	<b>Principal Investigator</b>	<b>Co-Investigator(s)</b>
Terry Fox Research Institute	Overcoming treatment failure in lymphoid cancers	<b>C</b>	\$7,500,000	2016-2021	<b>C. Steidl</b> J. Connors M. Marra D. Scott R. Morin S. Shah A. Weng	G. Morin G. Slack P. Farinha C. Hansen
Canadian Institutes of Health Research	The biology and clinical significance of the tumour microenvironment in B cell lymphomas	<b>C</b>	\$1,534,008	2016-2021	<b>C. Steidl</b>	G. Morin, M. Bally, K. Savage, S. Shah, A. Weng, G. Slack
Canadian Institutes of Health Research	Resolution of inter- and intra-tumoral heterogeneity in DLBCL using mass cytometry	C	\$860,064	2016 – 2021	A. Weng	<b>C. Steidl</b> , R. Brinkman
National Cancer Institute	Host factors, tumor microenvironment and survival in a multiethnic study of Hodgkin lymphoma patients	C	\$402,872	2016-2021	<b>C. Steidl</b>	
Children's Oncology Group	Identifying treatment response predictors in pediatric Hodgkin lymphoma	C	\$45,000	2016-2017	<b>C. Steidl</b>	
Cancer Research Society	Intratumoral Heterogeneity in Follicular Lymphoma: Insights into Clonal Evolution and Transformation Revealed by Mass Cytometry	C	\$120,000	2015-2017	A. Weng	<b>C. Steidl</b>
Lymphoma Research Foundation	Biomarkers predicting early treatment response in advanced stage classical Hodgkin lymphoma	C	\$100,000	2015-2017	D. Scott	R. Gascoyne, L. Rimsza, O. Press, <b>C. Steidl</b>
Canadian Institutes of Health Research	Somatic mutations in the JAK-STAT signaling pathway in primary mediastinal large B cell lymphoma	C	\$855,882	2014-2019	<b>C. Steidl</b>	M. Bally, R. Gascoyne, G. Morin
Leukemia and Lymphoma Society of Canada	The role of UBR5 mutations in the pathogenesis of mantle cell lymphoma	C	\$119,420	2014-2016	<b>C. Steidl</b>	R. Gascoyne

Genome British Columbia	Modelling Human Lymphoma Mutations in Mice	C	\$200,000	2014-2016	P. Hoodless, <b>C. Steidl</b> , K. Humphries	
Canadian Cancer Society Research Institute (CCSRI)	Detection of genomic rearrangements in archival lymphoma tissues using targeted capture sequencing	C	\$199,351	2014-2016	<b>C. Steidl</b>	R. Gascoyne, A. Mungall  Additional author: D. W. Scott
Leukemia & Lymphoma Society of Canada	Resolution of Intratumoral Heterogeneity in B-Cell NHL by Flow Cytometry	C	\$800,000	2014-2015	A. Weng	R. Brinkman, <b>C. Steidl</b> , R. Gascoyne
Terry Fox Research Institute (TFRI)	Molecular Correlates of Treatment Failure in Lymphoid Cancers	C	\$3,885,626	2013-2016	R. Gascoyne, J. Connors, S. Jones, M. Marra, S. Shah, <b>C. Steidl</b>	P. Hoodless, D. Scott
Genome Canada	Personalized Treatment of Lymphoid Cancer: British Columbia as Model Province	C	\$9,920,000	2013-2017	J. Connors, M. Marra, R. Gascoyne	<b>C. Steidl</b> , S. Peacock, S. Jones, I. Cromwell
Canadian Institutes of Health Research (CIHR) – New Investigator Award	Biology and clinical significance of the tumour microenvironment in lymphoid cancers	C	\$300,000	2013/07-2018/06	<b>C. Steidl</b>	
Michael Smith Foundation for Health Research – Career Investigator Scholar Award	Understanding tumor microenvironment interactions in lymphoid cancers: Transition into improved treatment outcome prediction and development of personalized therapies	C	\$635,000	2012/07-2020/06	<b>C. Steidl</b>	
Children's Oncology Group (COG) AYA	Identifying Treatment Response Predictors in Childhood Hodgkin Lymphoma	C	\$25,968 USD	2012-2014	T. Horton	<b>C. Steidl</b>
Canadian Institutes of Health Research	Prognostic markers and biology of relapsed Hodgkin lymphoma	C	\$502,157	2012-2015	<b>C. Steidl</b>	R. Gascoyne, S. Shah

Leukemia & Lymphoma Society of Canada	Recurrent somatic mutations of PTPN1 in B cell lymphomas	C	\$119,600	2012/07-2014/06	<b>C. Steidl</b>	
Canadian Hematology Society	Prognostic markers in relapsed Hodgkin lymphoma	C	\$10,000	2012	<b>C. Steidl</b>	
Canadian Institutes of Health Research	Centre for Epigenome Mapping Technologies	C	\$4,489,351 & \$10,649 (equip)	2012 – 2017	M. Marra, M. Hirst, S. Jones	<b>C. Steidl</b> , S. Aparicio, J. Connors, M. Cynader, C. Eaves, R. Gascoyne, D. Huntsman, A. Karsan, M. Kobor, A. Weng, S. Wiseman
Canadian Institutes of Health Research	Genetic mechanisms underlying immune privilege in malignant lymphomas	C	\$368,667	2011 - 2014	R. Gascoyne	<b>C. Steidl</b> , J. Connors
Leukemia and Lymphoma Society of Canada	Assessment of endogenous retroviral-mediated gene activation in lymphomas	C	\$119,900	07/11–06/13	D. Mager	<b>C. Steidl</b>
Canadian Institutes of Health Research	Predicting treatment response in Hodgkin Lymphoma by identifying new molecular markers	C	\$386,210	2008 – 2011	R. Gascoyne	<b>C. Steidl</b> , J. Connors
University of Goettingen	The impact of defective DNA repair on genetic changes in myelodysplastic syndromes and acute myeloid leukemias with complex chromosome rearrangements	C	\$30,000	2004 – 2005	<b>C. Steidl</b>	

(c) *Research or equivalent contracts (indicate under COMP whether grants were obtained competitively (C) or non-competitively (NC)).*

Granting Agency	Subject	COMP	\$ Per Year	Year	Principal Investigator	Co-Investigator(s)

(d) *Invited Presentations*

1. “Molecular assessment of the Hodgkin lymphoma tumor microenvironment” and “Outcome prediction in pediatric Hodgkin lymphoma”, Mayo Clinic, Rochester, Minnesota, June 25, 2016



2. "Acquired immune privilege in B-cell lymphomas", American Society of Hematology (ASH) Lymphoma Biology meeting, Colorado Springs, Colorado, June 19, 2016
3. "The tumor microenvironment in Hodgkin lymphoma", 1<sup>st</sup> Nordic meeting on tumor microenvironment in lymphoma, Aarhus, Denmark, May 19, 2016
4. "Targeting the tumor-host cellular interface in lymphoid malignancies", Keystone meeting on Stem Cells and Cancer, Breckenridge, Colorado, March 7, 2016
5. "The role of the tumor microenvironment in lymphoid malignancies", American Society of Hematology (ASH) meeting, Scientific Committee on Lymphoid Neoplasia, Orlando, FL, December 5-6, 2015
6. "Molecular assessment of the Tumour Microenvironment in Classical Hodgkin Lymphoma", Lymphoma Research Foundation AYA symposium, New York, October 2, 2015
7. "The mutational basis of immune privilege in B cell lymphomas", 11<sup>th</sup> Canadian CLL Research Meeting, Winnipeg, Manitoba, October 1, 2015
8. "Gene expression profiling and survival in classical Hodgkin lymphoma", International Lymphoma Epidemiology Consortium Annual Meeting, Workshop on Hodgkin lymphoma, Groningen, The Netherlands, June 22, 2015
9. "Genomic rearrangements involving programmed death ligands in lymphoid cancers", 8<sup>th</sup> Canadian Cancer Immunotherapy Consortium (CCIC) Symposium, Vancouver, BC, May 21, 2015
10. Children's Oncology Group Annual Meeting in Dallas, TX, USA 2014, "Tumor microenvironment and survival in classical Hodgkin lymphoma", September 17, 2014
11. Seminar series at Deeley Research Centre, British Columbia Cancer Agency, Victoria, BC, October 6, 2014, "Acquired immune privilege in B cell lymphomas"
12. LLS Canada Journey of Hope, "Lymphoma Research: Translating basic science into clinical application". Vancouver Jun11, 2014
13. Keynote Lecture at the International Lymphoma Epidemiology Consortium Annual Meeting June 17 2014, "Tumor microenvironment and survival in classical Hodgkin lymphoma"
14. Terry Fox Research Institute Annual Scientific Meeting, May 8, 2014, "Molecular Correlates of Treatment Failure in Lymphoid Cancers"
15. 2014 Canadian Human And Statistical Genetics Meeting, May 5, 2014, "Next generation sequencing of B cell lymphomas"
16. 2013 Canadian Cancer Research Conference Toronto, Outcome prediction in Hodgkin lymphoma - from discovery to clinical translation (Nov 6, 2013)
17. TFRI BC Node Research Day 2013, Vancouver, Molecular correlates of treatment failure in lymphoid cancer, October 13, 2013
18. 9th international Symposium on Hodgkin lymphoma, Cologne (Germany) 2013, Novel and recurrent coding sequence mutations in microdissected Hodgkin-/ Reed- Sternberg cells (October 12, 2013)
19. 2013 University Medical Center Groningen Seminar Series (Netherlands), Next generation sequencing of lymphoid cancers - what have we learned so far? (October 10, 2013)
20. Lymphoma Genomics: Diagnostic Precision Tools for Guiding Treatments: Canadian Society for Pharmaceutical Sciences Annual Symposium 2013, Vancouver, BC, June 2013
21. Next-generation Sequencing of Lymphoid Cancers: From Discovery to Clinical Translation, American Society of Hematology (ASH) meeting, Atlanta, GA, December 2012
22. Lymphoma Genomics – Discovery for Better Treatments, BCCA conference, 2012 Annual Cancer Conference of the BC Cancer Agency, Vancouver 2012
23. Impact of NGS on Molecular Hematopathology, Association for Molecular Pathology Meeting 2012, Long Beach, CA, October 2012
24. Next generation sequencing of B cell lymphomas: what have we learned so far? Seattle Blood Club, Seattle, WA, May 2012
25. Inactivating Gene Alterations of MHC Class II Transactivator *CIITA* Are Recurrent in Primary Mediastinal B Cell Lymphoma and Hodgkin Lymphoma. 53rd American Society of Hematology (ASH) meeting, San Diego, December 2011
26. CSF1R Expression of Hodgkin Reed Sternberg Cells Is Associated with the Number of Macrophages in the Tumor Microenvironment and Is Correlated with Treatment Outcome. 53rd American Society of Hematology (ASH) meeting, San Diego, December 2011
27. The Microenvironment in Hodgkin Lymphoma – Pathogenic and Clinical Relevance. The 2011 European Multidisciplinary Cancer Congress, Stockholm, Sweden, September 2011

28. Genomics in Hodgkin lymphoma: All roads lead to the tumour microenvironment. BC Cancer Agency's Vancouver Research Centre Seminar, Vancouver, July 2011
29. A molecular approach to Hodgkin Lymphoma: Understanding treatment failure. 1<sup>st</sup> International Symposium on Childhood Adolescent and Young Adult Hodgkin Lymphoma (ISCAYAHL), Arlington, VA, 2011, Invited lecture.
30. Fusion gene discovery in lymphoid cancers using next generation sequencing, Invited lecture, Cincinnati Children's Hospital Medical Center, Cincinnati 2011
31. 8<sup>th</sup> International Symposium on Hodgkin lymphoma, Cologne 2010: Genome-wide copy number analysis of microdissected HRS cells in classical Hodgkin lymphoma.
32. 2010 Annual Cancer Conference of the BC Cancer Agency, Vancouver 2010: Molecular characterization of Hodgkin lymphoma: Genome-wide approaches for biomarker discovery
33. Genomics approaches for biomarker discovery in Hodgkin lymphoma, Invited lecture, Albert-Einstein College of Medicine, New York 2010
34. Molecular characterization of Hodgkin lymphoma: Genome-wide approaches for biomarker discovery, Invited lecture, Weill Cornell Medical College, New York 2010
35. 51<sup>st</sup> American Society of Hematology (ASH) meeting, New Orleans 2009: Gene Expression Profiling of Microdissected Hodgkin Reed Sternberg Cells: Molecular Subtypes and Treatment Outcome Correlations
36. 50<sup>th</sup> American Society of Hematology (ASH) meeting, San Francisco 2008: Genetic Alterations Detected by High-Resolution Array Comparative Genomic Hybridization in Microdissected HRS Cells Correlate with Treatment Outcome in Classical Hodgkin Lymphoma
37. 50<sup>th</sup> American Society of Hematology (ASH) meeting, San Francisco 2008: Genome-Wide Expression Profiling Predicts Treatment Outcome in Classical Hodgkin Lymphoma
38. 7th International Symposium on Hodgkin Lymphoma, Cologne 2007, Germany: Gene expression profiling in Hodgkin Lymphoma: The HRS cells or the microenvironment?
39. The BC Cancer Immunotherapy Workshop, Vancouver, Canada, May 2007: Immune Microenvironment in Hodgkin Lymphoma
40. 17th Working Symposium of Tumour Cytogenetics, Hohwacht, Germany, May 2004: Karyotype evolution in myelodysplastic syndromes
41. 5th Annual Symposium of the German Competence Network „Acute and chronic Leukemias, Heidelberg, Germany, January 2004: Karyotype evolution and complex chromosome rearrangements in AML and MDS
42. 13th Annual Symposium of the German Society of Human Genetics, Leipzig, Germany, September 2002: Quality management in tumour cytogenetics.
43. 31st Meeting of the German Society of Pathology, Bonn, Germany, November 2000: Chromosomal aberrations in bladder cancer and adjacent urothelium

(e) *Other Presentations*

(f) *Other*

- 2014: Visiting scientist: Dr Wendy Cozen, Invited talk at Centre for Lymphoid Cancer Seminar series, "Epidemiology of Hodgkin lymphoma", November 19, 2014
- 2015: Industry collaboration with CTI Biopharma: Visit of Dr Jack Singer with researchers in the Centre for Lymphoid Cancer, May 19, 2015
- 2015: Industry collaboration with Trillium Therapeutics Inc., Visit Dr Eric Sievers with the Centre for Lymphoid Cancer (BCCA), November 20, 2015

(g) *Conference Participation (Organizer, Keynote Speaker, etc.)*

- 2010: Session chair of American Society of Hematology 2010 meeting, "Biology of Hodgkin Lymphoma"
- 2010: Scientific abstract reviewer for the American Society of Hematology meeting 2010, "Biology of Hodgkin Lymphoma"
- 2012: Scientific abstract reviewer for the American Society of Hematology meeting 2012, "Biology of Hodgkin Lymphoma"

- 2013: Coordinating Reviewer for the American Society of Hematology meeting 2013, "Biology of Hodgkin Lymphoma"
- 2013: Session Chair of the International Symposium on Hodgkin Lymphoma 2013, Workshop: Prognostic and biomarkers - tissue and serum/plasma
- 2013: Session Chair of American Society of Hematology 2013 meeting, "Biology of Hodgkin Lymphoma"
- 2014: Keynote Lecture at the International Lymphoma Epidemiology Consortium Annual Meeting. "Tumor microenvironment and survival in classical Hodgkin lymphoma"
- 2014: Member of scientific organizing committee for Terry Fox Research Institute Annual Scientific meeting 2014 in Montreal, Canada
- 2014: Session Chair: Terry Fox Research Institute Annual Scientific Meeting 2014, Workshop: Research Collaborations - Making Friends outside your discipline
- 2014: Poster judging: Terry Fox Research Institute Annual Scientific Meeting
- 2014: Member of the American Society of Hematology Scientific Committee on Lymphoid Neoplasia, planning for 2015 Annual meeting in Orlando
- 2014: Member of scientific program committee for Canadian Cancer Research Conference 2015 in Montreal, Canada
- 2015: Poster judging for 8<sup>th</sup> Canadian Cancer Immunotherapy Consortium (CCIC) Symposium, Vancouver, BC, May 2015
- 2015: Member of the Scientific Program Committee, 2015 Canadian Cancer Research Conference (Oct 2014 – Nov 2015)

## **10. SERVICE TO THE UNIVERSITY**

### *(a) Memberships on committees, including offices held and dates*

- 2012 - : Member of the BC Cancer Agency Research Centre Research Space Review Committee
- 2013 - : Department of Pathology (UBC), Outstanding Academic Performance & Merit Committee reviewer
- 2015 - Member of the UBC Pathology course curriculum committee (since 2015)
- 2015-2016: Member of the Search Committee for a Hematopathologist and Medical Director of the Provincial Lymphoma Pathology Program (BCCA Department of Pathology)
- 2016 - : Member of the BCCA Search Committee for the Vice President Research

### *(b) Other service, including dates*

- 2013: UBC Internal Reviewer for CIHR operating grant (fall competition)

## **11. SERVICE TO THE COMMUNITY**

### *(a) Memberships on scholarly societies, including offices held and dates*

1. Member, American Society of Hematology (since 2006)
2. Member, International Lymphoma Epidemiology Consortium (since 2014)
3. Member, Interlymph Hodgkin lymphoma working group (since 2014)

### *(b) Memberships on other societies, including offices held and dates*

### *(c) Memberships on scholarly committees, including offices held and dates*

1. Member, German-Austrian MDS study group, 2004 – Present
2. Member, Cytogenetics Committee, International Working Group on Prognosis in Myelodysplasia, 2008-Present

(d) *Memberships on other committees, including offices held and dates*

1. Member of the Lymphoma Research Foundation's Panel of Scientific Advisors (2012-2016)
2. Member of the Lymphoma Research Foundation's Scientific Advisory Board (since 2016)
3. Member of the Canadian Institutes of Health Research "Fellowships – Post-PhD" committee (since 2012)
4. Member of the Canadian Institutes of Health Research review panel "Cancer Progression and Therapeutics (CT2)" (since 2013)
5. Scientific reviewer for German Research Foundation (DFG) (since 2013)
6. Member of the Medical Expert Committee of the Cancer Research Society (since 2012)
7. American Society of Hematology Scientific Committee Member: Lymphoid Neoplasia (since 2013)
8. Member of review panel, Leukemia and Lymphoma Society, Quest for CURES competition, 2014
9. Member of the Canadian Cancer Society Research Institute review panel i4 (Innovation and Innovation to Impact grants), June 2015
10. Member of the Canadian Cancer Society Research Institute review panel i1A (Innovation and Innovation to Impact grants), December 2015
11. Scientific reviewer for Leukaemia & Lymphoma Research Bloodwise Specialist Programme (United Kingdom) (November 2015 – January 2016)

(e) *Editorships (list journal and dates)*

(f) *Reviewer (journal, agency, etc. including dates)*

1. Leukemia, 2005 – Present
2. Leukemia & Lymphoma, 2009 – Present
3. Haematologica, 2009 – Present
4. Blood, 2010 – Present
5. Leukemia Research, 2012- present
6. Experimental Hematology 2012-present
7. PLOS Genetics, 2012-present
8. Journal of Gastrointestinal Oncology, 2012-present
9. New England Journal of Medicine, 2012- present
10. Journal of Pathology, 2012 – present
11. Cancer Research, 2012- present
12. Current Biomarker findings, 2012 – present
13. Cytokine, 2013- present
14. Molecular Oncology, 2013 – present
15. Cancer Growth and Metastasis, 2013 – present
16. Cancer Cell International, 2013 – present
17. Nature Communications, 2013 – present
18. Diagnostic Pathology, 2013 – present
19. Cancer Cell, 2013 – present
20. Clinical Cancer Research, 2013 – present
21. Genes Chromosomes & Cancer, 2014 – present
22. Expert Review of Hematology, 2014 – present
23. Cell Reports, 2014 – present
24. Nature Genetics, 2015 – present
25. PLOS One, 2015 – present
26. Genome Biology, 2015 – present

(g) *External examiner (indicate universities and dates)*

(h) *Consultant (indicate organization and dates)*

1. Advisory Board: Affimed Therapeutics AG (June 2014)

(i) *Other service to the community*

1. Lay presentation to the Leukemia and Lymphoma Society of Canada: "Lymphoma Research: Translating basic science into clinical application", June 2014
2. Speaker / BCCA research representative at the 2015 Terry Fox Marathon of Hope community run in Coquitlam BC, September 20, 2015
3. Presentation to the BC Cancer Foundation Board of Directors, November 26, 2015

## **12. AWARDS AND DISTINCTIONS**

(a) *Awards for Teaching (indicate name of award, awarding organizations, date)*

(b) *Awards for Scholarship (indicate name of award, awarding organizations, date)*

1. Foerderungstipendium Scholarship, National German Scholarship Foundation (Germany), 1995-2001
2. Postdoctoral Fellowship Award, Deutsche Forschungsgemeinschaft (Germany), 2006-2008
3. Postdoctoral Fellowship Award, Cancer Research Society (Canada), 2008-2011
4. Postdoctoral Fellowship Award, Michael Smith Foundation for Health Research (Canada), 2008-2011
5. Postdoctoral Fellowship Award, Lymphoma Research Foundation (Canada), 2008-2010
6. Michael Smith Foundation for Health Research (MSFHR) 2012 Career Investigator Award, July 2012 – June 2020: "Understanding tumour microenvironment interactions in lymphoid cancers: Translation into improved treatment outcome prediction and development of personalized therapies"
7. Canadian Institutes of Health Research (CIHR) – New Investigator Award, July 2013 – June 2018; "Biology and clinical significance of the tumour microenvironment in lymphoid cancers"
8. Faculty of Medicine, Distinguished Achievement Award 2014, Excellence in Basic Science Research
9. Department of Pathology and Laboratory Medicine, Early Career Excellence in Research and Discovery Award 2014

(c) *Awards for Service (indicate name of award, awarding organizations, date)*

(d) *Other Awards*

1. Canadian Hematology Society 2011 Research Award, Junior Faculty, December 2011

## **13. OTHER RELEVANT INFORMATION (Maximum One Page)**

1. Principal Investigator of 2013 Banting Postdoctoral Fellowship award to Dr Daisuke Ennishi): Discovering the mutational landscape of Hodgkin lymphoma
2. Supervisor of 2012 "Best of ASH" abstract award by the Canadian Haematology Society (CHS) to Fong Chun Chan (PhD candidate)
3. Co-Principal investigator of 2012 CIHR postdoctoral fellowship award to Dr David Scott

4. Co-Principal investigator of 2012 CIHR postdoctoral fellowship award (Health Professionals) to Dr Robert Kridel
5. Co-Principal investigator of 2013 Michael Smith Foundation for Health Research (MSFHR) postdoctoral fellowship award to Dr Robert Kridel
6. Principal Investigator of 2014 Vanier Scholarship award to David Twa: Recurrent translocations involving programmed death ligands in non-Hodgkin lymphomas: Establishing a novel diagnostic biomarker and target for molecular-precise medicine
7. Supervisor of two best poster awards (to Jay Gunawardana) at 2015 Terry Fox Research Institute (TFRI) Annual meeting, St. John's, Newfoundland
8. Principal investigator of 2015 Michael Smith Foundation for Health Research (MSFHR) postdoctoral fellowship award to Dr Anja Mottok
9. Supervisor of two best poster awards (to Lauren Chong) at 2015 Terry Fox Research Institute (TFRI) Annual meeting, St. John's, Newfoundland

10. THE UNIVERSITY OF BRITISH COLUMBIA  
**Publications Record**

**SURNAME:** Steidl

**FIRST NAME:** Christian  
**MIDDLE NAME(S):** G

**Initials:**  
**Date:** March 4, 2016

**1. REFEREED PUBLICATIONS**

(a) *Journals*

1. **Steidl C.**, Simon R., Bürger H., Brinkschmidt C., Böcker W., Terpe H.J. Patterns of chromosomal aberrations in urinary bladder tumours and adjacent urothelium. *J Pathol* 2002 Sep; 198(1):115-20 PMID: 12210071
2. Steidl U., Schroeder T., **Steidl C.**, Kobbe G., Graef T., Bork S., Pechtel S., Kliszewski S., Kuendgen A., Rohr U.P., Fenk R., Schroeder M., Haase D., Haas R., Kronenwett R. Distinct Gene Expression Pattern of Malignant Hematopoietic Stem and Progenitor Cells in Polycythemia Vera. *Ann NY Acad Sci.* 2005 Jun; 1044: 94-108 PMID: 15958702
3. **Steidl C.**, Steffens R., Gassmann W., Hildebrandt B., Hilgers R., Germing U., Trümper L. and Haase D. Adequate cytogenetic examination in myelodysplastic syndromes: analysis of 529 patients. *Leuk Res.* 2005 Sep; 29(9):987-993 PMID: 16038724
4. Kuendgen A, Knipp S, Fox F, Strupp C, Hildebrandt B, **Steidl C**, Germing U, Haas R, HGattermann N. Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia. *Ann Hematol.* 2005 Dec;84 Suppl 1:61-6 PMID: 16270213
5. Germing U., Hildebrandt B., Pfeilstöcker M., Nösslinger T., Valent P., Fonatsch C., Lübbert M., Haase D., **Steidl C.**, Krieger O., Stauder R., Giagounidis AAN., Strupp C., Kündgen A., Mueller T., Haas R., Gattermann N., Aul C. Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS). *Leukemia.* 2005 Dec;19(12):2223-31
6. Kuendgen A., Schmid M., Schlenk R., Knipp S., Hildebrandt B., **Steidl C.**, Germing U., Haas R., Döhner H., Gattermann N. The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with *all-trans* retinoic acid in patients with acute myeloid leukemia. *Cancer.* 2006 Jan;106(1):112-9 PMID: 16323176
7. Steidl U, Rosenbauer F, Verhaak RG, Gu X, Ebralidze A, Otu HH, Klippel S, **Steidl C**, Bruns I, Costa DB, Wagner K, Aivado M, Kobbe G, Valk PJ, Passegue E, Libermann TA, Delwel R, Tenen DG. Essential role of Jun family transcription factors in PU.1 knockdown-induced leukemic stem cells. *Nat Genet.* 2006 Nov;38(11):1269-77. PMID: 17041602
8. Steidl U\*, **Steidl C\***, Ebralidze A, Chapuy B, Hye-Jung H, Will B, Rosenbauer F, Becker B, Wagner K, Koschmieder S, Kobayashi S, Schulz T, O'Brien KB, Verhaak RGW, Delwel R, Haase D, Truemper L, Krauter J, Kohwi-Shigematsu T, Griesinger F, Tenen DG. A single nucleotide polymorphism alters long-range regulation of the PU.1 gene in acute myeloid leukemia. *J Clin Invest.* 2007 Sep;117(9):2611-20 \*both authors contributed equally to this work PMID: 17694175
9. Haase D, Germing U, Schanz J, Pfeilstoecker M, Noesslinger T, Hildebrandt B, Kuendgen A, Luebbert M, Kunzmann R, Giagounidis A, Aul C, Truemper L, Krieger O, Stauder R, Mueller TH, Wimazal F, Valent P, Fonatsch C, **Steidl C**. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. *Blood.* 2007 Dec 15;110(13):4385-95. PMID: 17726160
10. **Steidl C**, Schanz J, Pfeilstoecker M, Noesslinger T, Hildebrandt B, Kuendgen A, Lübbert M, Kunzmann R, Giagounidis A, Aul C, Trümper L, Krieger O, Stauder R, Müller T, Wimazal F, Valent P, Fonatsch C, Germing U, Haase D. Growing Evidence for an Underestimation of Poor-Risk Cytogenetics in the

International Prognostic Scoring System in Myelodysplastic Syndromes. Clinical Leukemia. 2007 Dec; 1(6):353-356.

11. Cheung KJ, Shah SP, **Steidl C**, Johnson N, Relander T, Telenius A, Lai B, Murphy KP, Lam W, Al-Tourah AJ, Connors JM, Ng RT, Gascoyne RD, Horsman DE. HGenome-wide profiling of follicular lymphoma by array comparative genomic hybridization reveals prognostically significant DNA copy number imbalances. Blood. 2009 Jan 1;113(1):137-48. PMID: 18703704
12. Johnson NA, Savage KJ, Ludkovski O, Ben-Neriah S, Woods R, **Steidl C**, Dyer MJ, Siebert R, Kuruvilla J, Klasa R, Connors JM, Gascoyne RD, Horsman DE. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood. 2009 Sep 10;114(11):2273-9. PMID: 19597184
13. Shustik J, Han G, Farinha P, Johnson NA, Ben Neriah S, Connors JM, Sehn LH, Horsman DE, Gascoyne RD, **Steidl C**. Outcome correlations of BCL6 rearrangement in diffuse large B cell lymphoma treated with CHOP or R-CHOP. Haematologica. 2010 Jan;95(1):96-101. PMID: 19797725
14. Shah SP, Morin RD, Khattra J, Prentice L, Pugh T, Burleigh A, Delaney A, Gelmon K, Guliany R, Senz J, **Steidl C**, Holt RA, Jones S, Sun M, Leung G, Moore R, Severson T, Taylor GA, Teschendorff AE, Tse K, Turashvili G, Varhol R, Warren RL, Watson P, Zhao Y, Caldas C, Huntsman D, Hirst M, Marra MA, Aparicio S. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature. 2009 Oct 8;461(7265):809-13. PMID: 19812674
15. Murphy D, Parker J, Zhou M, Fadlilmola FM, **Steidl C**, Karsan A, Gascoyne RD, Chen H, Banerjee D. Constitutively overexpressed 21 kDa protein in Hodgkin lymphoma and aggressive non-Hodgkin lymphomas identified as cytochrome B5b (CYB5B). Mol Cancer. 2010 Jan 26;9:14. PMID: 20100355
16. **Steidl C**, Tang L, Shah SP, Farinha P, Han G, Nayar T, Delaney A, Jones SJ, Iqbal J, Weisenburger DD, Bast M, Rosenwald A, Muller-Hermelink HK, Rimsza L, Campo E, Delabie J, Braziel R, Cook JR, Tubbs RR, Jaffe ES, Lenz G, Connors JM, Staudt LM, Chan WC, Gascoyne RD. Tumor-associated macrophages and survival in classical Hodgkin lymphoma. N Engl J Med 362(10):875-85 (2010). PMID: 20220182
17. **Steidl C**, Telenius A, Shah SP, Farinha P, Barclay L, Boyle M, Connors JM, Horsman DE, Gascoyne RD. Genome-wide copy number analysis of Hodgkin Reed-Sternberg cells identifies recurrent imbalances with correlations to treatment outcome. Blood 116(3):418-27 (2010). PMID: 20339089
18. Cheung KJ, Johnson N, Affleck J, Severson T, **Steidl C**, Ben-Neriah S, Schein J, Morin RD, Moore R, Shah SP, Qian H, Paul J, Telenius A, Relander T, Lam WL, Savage KJ, Connors J, Brown C, Marra MA, Gascoyne RD, Horsman D. Acquired TNFRSF14 mutations in follicular lymphoma are associated with inferior prognosis. Cancer Res 70(22):9166-74 (2010). PMID: 20884631
19. Rui L, Emre NC, Kruhlak MJ, Chung HJ, **Steidl C**, Slack G, Wright GW, Lenz G, Ngo VN, Shaffer AL, Xu W, Zhao H, Yang Y, Lamy L, Davis RE, Xiao W, Powell J, Maloney D, Thomas CJ, Moller P, Rosenwald A, Ott G, Muller-Hermelink HK, Savage K, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Weisenburger DD, Chan WC, Gascoyne RD, Levens D, Staudt LM. Cooperative Epigenetic Modulation by Cancer Amplicon Genes. Cancer Cell 18(6):590-605 (2010). PMID: 21156283
20. Mallo M, Cervera J, Schanz J, Such E, García-Manero G, Luño E, **Steidl C**, Espinet B, Vallespí T, Germing U, Blum S, Ohyashiki K, Grau J, Pfeilstöcker M, Hernández J, Noesslinger T, Giagounidis A, Aul C, Calasanz J, Martín L, Valent P, Collado R, Haferlach C, Fonatsch C, Lübbert M, Stauder R, Hildebrandt B, Krieger O, Pedro C, Arenillas L, Sanz MA, Valencia A, Florensa L, Sanz GF, Haase D, Solé F. Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q. Leukemia 25(1):110-20 (2011). PMID: 20882045
21. **Steidl C**, Farinha P, Gascoyne RD. Macrophages predict treatment outcome in Hodgkin's lymphoma. Haematologica 96(2):186-9 (2011). PMID: 21282720
22. **Steidl C\***, Shah SP\*, Woolcock BW, Rui L, Kawahara M, Farinha P, Johnson NA, Zhao Y, Telenius A, Ben Neriah S, McPherson A, Meissner B, Okoye UC, Diepstra A, van den Berg A, Sun M, Leung G, Jones SJ, Connors JM, Huntsman DG, Savage KJ, Rimsza LM, Horsman DE, Staudt LM, Steidl U, Marra MA and Gascoyne RD. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature 471(7338):377-81 (2011). PMID: 21368758 *\*both authors contributed equally to this work*



23. Wiegand KC, Lee AF, Al-Agha OM, Chow C, Kalloger SE, Scott DW, **Steidl C**, Wiseman SM, Gascoyne RD, Gilks B, Huntsman DG. Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas. Journal of Pathology 224(3):328-33 (2011). PMID: 21590771
24. Schanz J, **Steidl C**, Fonatsch C, Pfeilstöcker M, Nösslinger T, Tuechler H, Valent P, Hildebrandt B, Giagounidis A, Aul C, Lübbert M, Stauder R, Krieger O, Garcia-Manero G, Kantarjian H, Germing U, Haase D and Estey E. Coalesced multicentric analysis of 2351 patients with MDS indicates an underestimation of poor risk cytogenetics in the International Prognostic Scoring System of myelodysplastic syndromes. Journal of Clinical Oncology. 29(15):1963-70 (2011). PMID: 21519021
25. **Steidl C**, Connors JM and Gascoyne RD. The Molecular Pathogenesis of Hodgkin Lymphoma: Increasing Evidence of the Importance of the Microenvironment. Journal of Clinical Oncology 10;29(14):1812-26 (2011). PMID: 21483001
26. Eberle FC\*, Salaverria I\*, **Steidl C\***, Summers Jr TA, Pittaluga S, Ben Neriah S, Rodriguez-Canales J, Xi L, Ylaya K, Liewehr D, Dunleavy K, Wilson WH, Hewitt SM, Raffeld M, Gascoyne RD, Siebert R, Jaffe ES. Gray zone lymphoma: chromosomal aberrations with immunophenotypic and clinical correlations. Modern Pathology. 2011 Aug 5 [Epub ahead of print] PMID: 21822207 *\*authors contributed equally to this work*
27. **Steidl C** and Gascoyne RD. The molecular pathogenesis of primary mediastinal large B cell lymphoma. Blood. 118(10):2659-69 (2011). PMID: 21700770
28. Kridel R, Meissner B, Rogic S, Boyle M, Telenius A, Woolcock B, Gunawardana J, Jenkins C, Cochrane C, Ben-Neriah S, Tan K, Opat S, Sehn LH, Connors JM, Weng AP, **Steidl C\***, Gascoyne RD\*. Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma. Blood. 2012;119(9):1963-71. PMID: 22210878 *\*both authors contributed equally to this work*
29. Schanz J, Tüchler H, Solé F, Mallo M, Luño E, Cervera J, Granada I, Hildebrandt B, Slovak ML, Ohyashiki K, **Steidl C**, Fonatsch C, Pfeilstöcker M, Nösslinger T, Valent P, Giagounidis A, Aul C, Lübbert M, Stauder R, Krieger O, Garcia-Manero G, Faderl S, Pierce S, Le Beau MM, Bennett JM, Greenberg P, Germing U, Haase D. New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge. J Clin Oncol. 2012;30(8):820-9. PMID: 22331955
30. Xie L, Ushmorov A, Leithäuser F, Guan H, **Steidl C**, Färbing J, Pelzer C, Vogel MJ, Maier HJ, Gascoyne RD, Möller P, Wirth T. FOXO1 is a tumor suppressor in classical Hodgkin lymphoma. Blood. 2012;119(15):3503-11. PMID: 22343918
31. Scott DW, Mungall KL, Ben-Neriah S, Rogic S, Morin RD, Slack GW, Tan KL, Chan FC, Lim RS, Connors JM, Marra MA, Mungall AJ, **Steidl C**, Gascoyne RD. TBL1XR1/TP63: a novel recurrent gene fusion in B-cell non-Hodgkin lymphoma. Blood 2012;119(21):4949-52. PMID: 22496164
32. Barreyro L, Will B, Bartholdy B, Zhou L, Todorova TI, Stanley RF, Ben-Neriah S, Montagna C, Parekh S, Pellagatti A, Boulwood J, Paietta E, Ketterling RP, Cripe L, Fernandez HF, Greenberg PL, Tallman MS, **Steidl C**, Mitsiades CS, Verma A, Steidl U. Overexpression of interleukin 1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS. Blood 2012; 120(6):1290-8. PMID: 22723552
33. Will B, Zhou L, Vogler TO, Ben-Neriah S, Schinke C, Tamari R, Yu Y, Bhagat T, Bhattacharya S, Barreyro L, Heuck C, Mo Y, Parekh S, McMahon C, Pellagatti A, Boulwood J, Montagna C, Silverman L, Maciejewski J, Greally JM, Ye BH, List AF, **Steidl C**, Steidl U, Verma A. Stem and progenitor cells in myelodysplastic syndromes show aberrant stage specific expansion and harbor genetic and epigenetic alterations. Blood. 2012;120(10):2076-86. PMID: 22753872
34. Johnson NA, Slack GW, Savage KJ, Connors JM, Ben-Neriah S, Rogic S, Scott DW, Tan KL, **Steidl C**, Sehn LH, Chan WC, Iqbal J, Meyer PN, Lenz G, Wright G, Rimsza LM, Valentino C, Brunhoeber P, Grogan TM, Braziel RM, Cook JR, Tubbs RR, Weisenburger DD, Campo E, Rosenwald A, Ott G, Delabie J, Holcroft C, Jaffe ES, Staudt LM, Gascoyne RD. Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. J Clin Oncol. 2012. Oct 1;30(28):3452-9 PMID: 22851565
35. Tan KL, Scott DW, Hong F, Kahl BS, Fisher RI, Bartlett NL, Advani RH, Buckstein R, Rimsza LM, Connors JM, **Steidl C**, Gordon LI, Horning SJ, Gascoyne RD. Tumor-associated macrophages predict inferior outcomes in classical Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial. Blood 2012 Oct 18;120(16):3280-7. PMID: 22948049

36. **Steidl C**, Diepstra A, Lee T, Chan FC, Farinha P, Tan K, Telenius A, Barclay L, Shah SP, Connors JM, van den Berg A, Gascoyne RD. Gene expression profiling of microdissected Hodgkin Reed Sternberg cells correlates with treatment outcome in classical Hodgkin lymphoma. Blood 2012 Oct 25;120(17):3530-40. PMID: 22955918
37. Scott DW, Chan FC, Hong F, Rogic S, Tan K, Meissner B, Ben-Neriah S, Boyle M, Kridel R, Telenius A, Woolcock B, Farinha P, Fisher R, Rimsza L, Bartlett N, Cheson B, Shepherd L, Advani R, Connors JM, Kahl B, Gordon L, Horning S, **Steidl C**, Gascoyne RD. A Gene Expression-Based Model Using Formalin-Fixed Paraffin-Embedded Biopsies Predicts Overall Survival in Advanced Stage Classical Hodgkin Lymphoma. Journal of Clinical Oncology. 2013;31(6):692-700. PMID: 23182984
38. Bjordahl RL, Steidl C, Gascoyne RD, Ware CF. Lymphotoxin network pathways shape the tumor microenvironment. Curr Opin Immunol 2013;25(2):222-9. PMID: 23339845
39. Meissner B, Kridel R, Lim RS, Rogic S, Tse K, Scott DW, Moore R, Mungall AJ, Marra MA, Connors JM, **Steidl C\***, Gascoyne RD\*. The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphoma. Blood. 2013;121(16):3161-4. PMID: 23407552 *\*both authors contributed equally to this work*
40. Diefenbach CS, **Steidl C**. New Strategies in Hodgkin Lymphoma: Better Risk Profiling and Novel Treatments. Clin Cancer Res. 2013;19(11):2797-803. PMID: 23447000
41. Trinh DL, Scott DW, Morin RD, Mendez-Lago M, An J, Jones SJ, Mungall AJ, Zhao Y, Schein J, **Steidl C**, Connors JM, Gascoyne RD, Marra MA. Analysis of FOXO1 mutations in diffuse large B-cell lymphoma. Blood. 2013;121(18):3666-74. PMID: 23460611
42. Hartmann S, Tousseyn T, Doring C, Fluchter P, Hackstein H, Herreman A, Ponzoni M, de Wolf-Peeters C, Facchetti F, Gascoyne RD, Kuppers R, **Steidl C**, Hansmann ML. Macrophages in T cell/histiocyte rich large B cell lymphoma strongly express metal-binding proteins and show a bi-activated phenotype. Int J Cancer. 2013 Dec 1;133(11):2609-18. PMID: 23686423
43. Morin RD, Mungall K, Pleasance E, Mungall AJ, Goya R, Huff R, Scott DW, Ding J, Roth A, Chiu R, Corbett RD, Chan FC, Mendez-Lago M, Trinh DL, Bolger-Munro M, Taylor G, Hadj Khodabakhshi A, Ben-Neriah S, Pon J, Meissner B, Woolcock B, Farnoud N, Rogic S, Lim E, Johnson NA, Shah S, Jones S, **Steidl C**, Holt R, Birol I, Moore R, Connors JM, Gascoyne RD, Marra MA. Mutational and structural analysis of diffuse large B-cell lymphoma using whole genome sequencing. Blood. 2013. Aug 15;122(7):1256-65. PMID: 23699601
44. Schanz J, Tüchler H, Solé F, Mallo M, Luño E, Cervera J, Grau J, Hildebrandt B, Slovak ML, Ohyashiki K, **Steidl C**, Fonatsch C, Pfeilstöcker M, Nösslinger T, Valent P, Giagounidis A, Aul C, Lübbert M, Stauder R, Krieger O, Le Beau MM, Bennett JM, Greenberg P, Germing U, Haase D. Monosomal karyotype in MDS: explaining the poor prognosis? Leukemia. 2013 Oct;27(10):1988-95. PMID: 23787396
45. Hartmann S, Döring C, Jakobus C, Rengstl B, Newrzela S, Tousseyn T, Sagaert X, Ponzoni M, Facchetti F, de Wolf-Peeters C, **Steidl C**, Gascoyne R, Küppers R, Hansmann ML. Nodular lymphocyte predominant hodgkin lymphoma and T cell/histiocyte rich large B cell lymphoma - endpoints of a spectrum of one disease? PLoS One. 2013 Nov 11;8(11):e78812. PMID: 24244368
46. Rahal R, Frick M, Romero R, Korn JM, Kridel R, Chun Chan F, Meissner B, Bhang HE, Ruddy D, Kauffmann A, Farsidjani A, Derti A, Rakiec D, Naylor T, Pfister E, Kovats S, Kim S, Dietze K, Dörken B, **Steidl C**, Tzankov A, Hummel M, Monahan J, Morrissey MP, Fritsch C, Sellers WR, Cooke VG, Gascoyne RD, Lenz G, Stegmeier F. Pharmacological and genomic profiling identifies NF- $\kappa$ B-targeted treatment strategies for mantle cell lymphoma. Nature Medicine. 2014 Jan;20(1):87-92. PMID: 24362935
47. Gunawardana J, Chan FC, Telenius A, Woolcock B, Kridel R, Tan KL, Ben-Neriah S, Mottok A, Lim RS, Boyle M, Rogic S, Rimsza LM, Guiter C, Leroy K, Gaulard P, Haioun C, Marra MA, Savage KJ, Connors JM, Shah SP, Gascoyne RD, **Steidl C**. Recurrent Somatic Mutations of *PTPN1* in Primary Mediastinal B cell lymphoma and Hodgkin Lymphoma. Nature Genetics. 2014;46(4):329-35. PMID: 24531327
48. Twa D, Fong C, Ben-Neriah S, Woolcock BW, Tan KL, Slack GW, Gunawardana J, Lim RS, McPherson AW, Kridel R, Telenius A, Scott DW, Savage KJ, Shah SP, Gascoyne RD, **Steidl C**. Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma. Blood. 2014;123(13):2062-5. PMID: 24497532
49. Gascoyne RD, **Steidl C**. Hodgkin lymphoma: from discovery to clinical translation. Pathology. 2014 Feb;46 Suppl 1:S31-2. PMID: 24557250

50. Liu Y, Razak FR, Terpstra M, Chan FC, Saber A, Nijland M, van Imhoff G, Visser L, Gascoyne R, **Steidl C**, Kluiver J, Diepstra A, Kok K, van den Berg A. The mutational landscape of Hodgkin lymphoma cell lines determined by whole exome sequencing. *Leukemia*. 2014 Nov;28(11):2248-51. PMID: 24947018
51. Slack GW, **Steidl C**, Sehn L, Gascoyne RD. CD30 expression in *de novo* diffuse large B-cell lymphoma: a population based study from British Columbia. *Br J Haematol*. 2014 Dec;167(5):608-17. PMID: 25135752
52. Lock FE, Rebollo R, Miceli-Royer K, Gagnier L, Kuah S, Babaian A, Sistiaga-Poveda M, Lai CB, Nemirovsky O, Serrano I, **Steidl C**, Karimi MM, Mager DL. A distinct isoform of FABP7 revealed by screening for retroelement activated genes in diffuse large B-cell lymphoma. *Proc Natl Acad Sci U S A*. 2014 Aug 26;111(34):E3534-43. PMID: 25114248
53. Kendrick S, Redd L, Muranyi A, Henricksen LA, Stanislaw S, Smith LM, Perry AM, Fu K, Weisenburger DD, Rosenwald A, Ott G, Gascoyne RD, Jaffe ES, Campo E, Delabie J, Braziel RM, Cook JR, Tubbs RR, Staudt M, Chan WC, **Steidl C**, Grogan TM, Rimsza L. BCL2 Antibodies Targeted At Different Epitopes Detect Varying Levels of Protein Expression and Correlate with Frequent Gene Amplification in Diffuse Large B Cell Lymphoma. *Hum Pathol*. 2014 Oct;45(10):2144-53. PMID:25090918
54. Vogel MJ, Xie L, Guan H, Tooze RM, Maier T, Kostezka U, Maier HJ, Holzmann K, Chun Chan F, **Steidl C**, Reichel JB, Weitzer CD, Gehringer F, Kick AB, Cesarman E, Roshal M, Gascoyne RD, Möller P, Wirth T, Ushmorov A. FOXO1 repression contributes to block of plasma cell differentiation in classical Hodgkin Lymphoma. *Blood*. 2014 Nov 13;124(20):3118-29 PMID: 25232062
55. Scott DW, **Steidl C**. The classical Hodgkin lymphoma tumor microenvironment: macrophages and gene expression-based modeling. *Hematology Am Soc Hematol Educ Program* 2014 Dec 5;2014(1):144-50. PMID: 25696847
56. Twa DD, **Steidl C**. Structural genomic alterations in primary mediastinal large B-cell lymphoma. *Leuk Lymphoma*. 2015 Jan 21:1-12. PMID: 25393674
57. Lim EL, Trinh DL, Scott DW, Chu A, Krzywinski M, Zhao Y, Robertson AG, Mungall AJ, Schein J, Boyle M, Mottok A, Ennishi D, Johnson NA, **Steidl C**, Connors JM, Morin RD, Gascoyne RD, Marra MA. Comprehensive miRNA sequence analysis reveals survival differences in diffuses large b-cell lymphoma patients. *Genome Biol*. 2015 Jan 29; 16:18. PMID: 25723320
58. Chan FC, Telenius A, Healy S, Ben-Neriah S, Mottok A, Lim R, Drake M, Hu S, Ding J, Ha G, Scott DW, Kridel R, Bashashati A, Rogic S, Johnson N, Morin RD, Rimsza LM, Sehn L, Connors JM, Marra MA, Gascoyne RD, Shah SP, **Steidl C**. An RCOR1 loss-associated gene expression signature identifies a prognostically significant DLBCL subgroup. *Blood*. 2015 Feb 5;125(6):959-66. PMID: 25395426
59. Bushell KR, Kim Y, Chan FC, Ben-Neriah S, Jenks A, Alcaide M, Fornika D, Grande B, Arthur S, Gascoyne RD, **Steidl C**, Morin RD. Genetic inactivation of TRAF3 in canine and human B-cell lymphoma. *Blood*. 2015 Feb 5;125(6):999-1005. PMID: 25468570
60. Kridel R, **Steidl C**, Gascoyne RD. Tumor-associated macrophages in diffuse large B-cell lymphoma. *Haematologica*. 2015 Feb;100(2):143-5. PMID: 25638802
61. Hartmann S, Döring C, Vucic E, Chan FC, Ennishi D, Tousseyn T, de Wolf-Peeters C, Perner S, Wlodarska I, **Steidl C**, Gascoyne RD, Hansmann ML. Array comparative genomic hybridization reveals similarities between nodular lymphocyte predominant Hodgkin lymphoma and T cell/histiocyte rich large B cell lymphoma. *Br J Haematol*. (Epub Feb 2, 2015) PMID: 25644177
62. Twa DD, Mottok A, Chan FC, Ben-Neriah S, Woolcock BW, Tan KL, Mungall AJ, McDonald H, Zhao Y, Lim RS, Nelson BH, Milne K, Shah SP, Morin RD, Marra MA, Scott DW, Gascoyne RD, **Steidl C**. Recurrent genomic rearrangements in primary testicular lymphoma. *J Pathol* (Epub Feb 25, 2015) PMID: 25712539
63. Dunleavy K, **Steidl C**. Emerging biological insights and novel treatments strategies in primary mediastinal large B-cell lymphoma. *Semin Hematol*. 2015 Apr;52(2):119-125. PMID:25805591
64. Kridel R, Xerri L, Gelas-Dore B, Tan K, Feugier P, Vawda A, Canioni D, Farinha P, Boussetta S, Moccia AA, Brice P, Chavez EA, Kyle AH, Scott DW, Sanders A, Fabiani B, Slack G, Minchinton AI, Haioun C, Connors JM, Sehn L, **Steidl C**, Gascoyne RD, Salles G. The prognostic impact of CD163-positive macrophages in follicular lymphoma: A study from the BC Cancer Agency and the Lymphoma Study Association. *Clin Cancer Res* (Epub April 13, 2015) PMID: 25869385
65. Mottok A, **Steidl C**. Genomic alternations underlying immune privilege in malignant lymphomas. *Curr Opin Hematol* 2015 Jul;22(4):343-54. PMID: 26049756

66. Yuan J, Wright G, Rosenwald A, **Steidl C**, Gascoyne RD, Connors JM, Mottok A, Weisenburger DD, Greiner TC, Fu K, Smith L, Rimsza LM, Jaffe ES, Campo E, Martinez A, Delabie J, Braziel RM, Cook JR, Ott G, Vose JM, Staudt LM, Chan WC; Lymphoma Leukemia Molecular Profiling Project (LLMPP). Identification of Primary Mediastinal Large B-Cell Lymphoma at Nonmediastinal Sites by Gene Expression Profiling. *Am J Surg Pathol* (Epub May 11, 2015) PMID: 26135560
67. Scott DW, Mottok A, Ennishi D, Wright GW, Farinha P, Ben-Neriah S, Kridel R, Barry GS, Hother C, Abrisqueta P, Boyle M, Meissner B, Telenius A, Savage KJ, Sehn LH, Slack GW, **Steidl C**, Staudt LM, Connors JM, Rimsza LM, Gascoyne RD. Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies. *J Clin Oncol* (Epub Aug 3, 2015) PMID: 26240231
68. Wang C, McKeithan TW, Gong Q, Zhang W, Bouska A, Rosenwald A, Gascoyne RD, Wu X, Wang J, Muhammad Z, Jiang B, Rohr J, Cannon A, **Steidl C**, Fu K, Li Y, Hung S, Weisenburger DD, Greiner TC, Smith L, Ott G, Rogan EG, Staudt LM, Vose J, Iqbal J, Chan WC. IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma. *Blood* (Epub Aug 12, 2015) PMID: 26268241
69. Babaian A, Romanish MT, Gagnier L, Kuo LY, Karimi MM, **Steidl C**, Mager DL. Onco-exaptation of an endogenous retroviral LTR drives IRF5 expression in Hodgkin lymphoma. *Oncogene*. 2015 Aug 17. doi: 10.1038/onc.2015.308. [Epub ahead of print]
70. Kridel R, Mottok A, Farinha P, Ben-Neriah S, Ennishi D, Zheng Y, Chavez EA, Shulha HP, Tan K, Chan FC, Boyle M, Meissner B, Telenius A, Sehn LH, Marra MA, Shah SP, **Steidl C**, Connors JM, Scott DW, Gascoyne RD. Cell of origin of transformed follicular lymphoma. *Blood* 2015 Oct 29;126(18):2118-27. PMID: 26307535
71. **Steidl C**. A two-pronged attack against mantle cell lymphoma. *Blood* 2015 Sep 24;126(13):1521-3. PMID: 26405213
72. Mottok A, Woolcock B, Chan FC, Tong KM, Chong L, Farinha P, Telenius A, Chavez E, Ramchandani S, Drake M, Boyle M, Ben-Neriah S, Scott DW, Rimsza LM, Siebert R, Gascoyne RD, **Steidl C**. Genomic Alterations in CIITA Are Frequent in Primary Mediastinal Large B Cell Lymphoma and Are Associated with Diminished MHC Class II Expression. *Cell Rep* 2015 Nov 17;13(7):1418-31. PMID: 26549456
73. Rohr J, Guo S, Huo J, Bouska A, Lachel C, Li Y, Simone PD, Zhang W, Gong Q, Wang C, Cannon A, Heavican T, Mottok A, Hung S, Rosenwald A, Gascoyne R, Fu K, Greiner TC, Weisenburger DD, Vose JM, Staudt LM, Xiao W, Borgstahl GE, Davis S, **Steidl C**, McKeithan T, Iqbal J, Chan WC. Recurrent activating mutations of CD28 in peripheral T-cell lymphomas. *Leukemia* (Epub December 31, 2015) PMID: 26719098
74. Savage KJ, Slack GW, Mottok A, Sehn LH, Villa D, Kansara R, Kridel R, **Steidl C**, Ennishi D, Tan KL, Ben-Neriah S, Johnson NA, Connors JM, Farinha P, Scott DW, Gascoyne RD. The impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL. *Blood* (Epub Feb 1, 2016) PMID: 26834242
75. Chong LC, Twa DD, Mottok A, Ben-Neriah S, Woolcock BW, Zhao Y, Savage KJ, Marra MA, Scott DW, Gascoyne RD, Morin RD, Mungall AJ, **Steidl C**. Comprehensive characterization of programmed death ligand structural rearrangements in B-cell non-Hodgkin lymphomas. *Blood* 2016 Jun 7. pii: blood-2015-11-683003. (Epub ahead of print) PMID: 27268263

(b) *Conference Proceedings*

1. R. Simon, **C. Steidl**, H. Bürger, E. Eltze, L. Hertle, W. Böcker, H.-J. Terpe. Copy number changes of chromosome 11 in superficial bladder cancer. *Pathol. Res. Pract.* 195 (1999) 5, 303.
2. **C. Steidl**, R. Simon, H.-J. Terpe. Chromosomale Aberrationen in Harnblasenkarzinomen und angrenzendem Urothel. *Pathologe*, 22 (2001) 3, 228.
3. D. Haase, W. Gassmann, E. Stitz, R. Steffens, U. Söling, F. Griesinger, K. Karcher-Kilian, C. Binder, T. Schulz, W.-D. Ludwig, **C. Steidl**, J. Schanz, L. Trümper, B. Wörmann. Effects of amifostine on transfusion need, Blood counts and clinical course in patients with MDS (IPSS<1.5) – a phase III trial. *Onkologie* 2003; 26: 120.
4. **C. Steidl**, L.H. Trümper, D. Haase. P53- and ATM-Locus deletions in myelodysplastic syndromes and Acute Myeloid Leukemias with complex karyotypes. *Blood*. 2003; 102: 220b.

5. **C. Steidl**, B. Hildebrandt, U. Germing, L.H. Trümper, D. Haase. Cytogenetic metaphase analysis in Myelodysplastic Syndromes – Diagnostic accuracy is significantly dependent on the number of metaphases analyzed. *Blood*. 2003; 102: 330b.
6. **C. Steidl**, R. Schabla, U. Germing, B. Hildebrandt, T. Nösslinger, M. Pfeilstöcker, P. Haas, M. Lübbert, L.H. Trümper, D. Haase. Sequential cytogenetic analysis of 322 patients with myelodysplastic syndromes. Delineation of genetic evolution and clinical implications. *Blood*. 2004; 104: 651a.
7. **C. Steidl**, R. Schabla, U. Germing, B. Hildebrandt, T. Noesslinger, M. Pfeilstöcker, A. Giagounidis, R. Kunzmann, P. Haas, M. Luebbert, L. Truemper, D. Haase. Sequential Cytogenetic Analyses of 577 Patients with Myelodysplastic Syndromes: Correlations between Initial Karyotype, Cytogenetic Dynamics, and Clinical Course. *Blood*, Nov 2005; 106: 2531.
8. D. Haase, **C. Steidl**, A. Bierbaum, U. Soeling, L. Truemper, and F. Griesinger. Different Patterns of Cytogenetic Evolution in CML Treated with Imatinib. *Blood*, Nov 2005; 106: 4496.
9. D. Haase, U. Germing, J. Schanz, M. Pfeilstöcker, T. Noesslinger, B. Hildebrandt, A. Kuendgen, M. Luebbert, A. Giagounidis, C. Aul, L. Truemper, T. Mueller, P. Valent, C. Fonatsch, and **C. Steidl**. New and Comprehensive Cytogenetic Prognostication and Categorization in MDS. *Blood*, Nov 2006; 108: 248.
10. D. Haase, U. Germing, J. Schanz, M. Pfeilstöcker, B. Hildebrandt, M. Luebbert, A. Giagounidis, C. Aul, L. Truemper, T. Mueller, P. Valent, N. Gattermann, C. Fonatsch, O. Krieger, R. Stauder, and **C. Steidl**. Evidence for an Underestimation of the Prognostic Impact of Poor Cytogenetics within the IPSS. *Blood*, Nov 2006; 108: 252.
11. **C. Steidl**, T. Nayar, T. Lee, A. Telenius, N. Johnson, D. Horsman, J. Connors, R.D. Gascoyne. Gene expression profiling of microdissected HRS cells in classical Hodgkin Lymphoma. *Haematologica* 2007.
12. R.D. Gascoyne, T. Nayar, T. Lee, N. Johnson, J.M. Connors and **C. Steidl**. Predicting outcome in classical Hodgkin Lymphoma: the role of the microenvironment. *Haematologica* 2007.
13. **C. Steidl**, A. Telenius, J. Connors, D. Horsman and R.D. Gascoyne. Genetic imbalances in microdissected HRS cells: patterns of alterations and differences between treatment responders and failures. *Haematologica* 2007.
14. U. Steidl, **C. Steidl**, A. Ebralidze, B. Chapuy, H.-J. Han, B. Will, F. Rosenbauer, A. Becker, K., S. Koschmieder, S. Kobayashi, D.B. Costa, T. Schulz, K.B. O'Brien, R.G.W. Verhaak, R. Delwel, D. Haase, L. Truemper, J. Krauter, T. Kohwi-Shigematsu, F. Griesinger, and D.G. Tenen. A Distal Single Nucleotide Polymorphism Disrupts Development-Dependent Long-Range Transcriptional Regulation of the PU.1 Gene through the Chromatin-Remodeling Protein SATB1 in Acute Myeloid Leukemia. *Blood*, Nov 2007; 110: 3175.
15. K.-J. Cheung, A. Telenius, B. Lai, N. Johnson, T. Relander, **C. Steidl**, A. Baross, H. Qian, J. Schein, M. Marra, J.M. Connors, R.D. Gascoyne, and D.E. Horsman. High Frequency of 1p36.32 Deletion or Loss of Heterozygosity in Follicular Lymphoma (FL). *Blood*, Nov 2007; 110: 183.
16. Friederike Bräulke, Julie Schanz, **C. Steidl**, Lorenz H. Truemper, and Detlef Haase. FISH-Analyses of Circulating CD34+ Cells in MDS-Patients - A Suitable Method To Measure and Predict Response to 5-Azacytidine. *Blood*, Nov 2007; 110: 2466.
17. **C. Steidl**, J. Schanz, M.M. Le Beau, J.M. Bennett, U. Germing, P.L. Greenberg, and D. Haase. Coalescence of the German-Austrian and IMRAW Cytogenetic MDS Databases: Modification of Patient Risk Groups. *Blood*, Nov 2007; 110: 2468.
18. D. Haase, E.H. Estey, **C. Steidl**, U. Germing, G. Garcia-Manero, H.M. Kantarjian, and J. Schanz. Multivariate Evaluation of the Prognostic and Therapeutic Relevance of Cytogenetics in a Merged European-American Cohort of 3860 Patients with MDS. *Blood*, Nov 2007; 110: 247.
19. J. Schanz, E.H. Estey, **C. Steidl**, U. Germing, B. Hildebrandt, G. Garcia-Manero, H.M. Kantarjian, and D. Haase. Multivariate Analysis Suggests That the Prognostic Impact of Poor Cytogenetics Is Potentially Underestimated in the IPSS. *Blood*, Nov 2007; **110**: 248.
20. J. Schanz, M.L. Slovak, K. Ohyashiki, F. Solé, M. del Mar Mallo, **C. Steidl**, M. Pfeilstöcker, T. Noesslinger, B. Hildebrandt, M. Luebbert, M.K. Andersen, A. Giagounidis, P. Valent, C. Fonatsch, U. Germing, and D. Haase. New Prognostic Data on Rare Cytogenetic Abnormalities in MDS: A Collaborative Study of the International Working Group on MDS Cytogenetics. *Blood*, Nov 2008; 112: 2688.
21. M. del Mar Mallo, J. Cervera, J. Schanz, B. Espinet, E. Such, E. Luño, **C. Steidl**, M.L. Martín, U. Germing, J. Grau, M. Pfeilstöcker, J.M. Hernández, T. Noesslinger, M. a José Calasanz, P. Valent, R. Collado, C. Fonatsch, E. Bureo, M. Lübbert, R. Ríos, R. Stauder, E. Arranz, B. Hildebrandt, M.L. Slovak, J. Cigudosa, V. Eclache, O. Krieger, C. Pedro, M. Salido, L. Arenillas, G. Sanz, M.A. Sanz, A. Valencia, L. Florensa, D.

- Haase, and F. Solé Prognostic Impact of Additional Chromosomal Aberrations (ACA) to 5q- in Patients with primary Myelodysplastic Syndrome. *Blood*, Nov 2008; 112: 1649.
22. **C. Steidl**, T. Lee, S. P. Shah, G. Han, T. Nayar, A. Delaney, S. Jones, W.C. Chan, A. Rosenwald, L.M. Rimsza, E.Campo, E.S. Jaffe, L.M. Staudt, G. Lenz, J.M. Connors, and R.D. Gascoyne. Genome-Wide Expression Profiling Predicts Treatment Outcome in Classical Hodgkin Lymphoma. *Blood*, Nov 2008; 112: 520.
  23. **C. Steidl**, Adele Telenius, Sohrab P. Shah, K-John Cheung, Lorena Barclay, Joseph M. Connors, Douglas E. Horsman, and Randy D. Gascoyne. Genetic Alterations Detected by High-Resolution Array Comparative Genomic Hybridization in Microdissected HRS Cells Correlate with Treatment Outcome in Classical Hodgkin Lymphoma. *Blood*, Nov 2008; 112: 522.
  24. N.A. Johnson, K.J. Savage, S. Ben-Neriah, **C. Steidl**, R. Klasa, J.M. Connors, R.D. Gascoyne, and D.E. Horsman. Lymphomas with Concurrent T(14;18) and 8q24 Translocations Are Under- Reported and Clinical Outcome Depends on the MYC Partner. *Blood*, Nov 2008; 112: 804.
  25. J. Shustik, **C. Steidl**, L. Sehn, and R.D. Gascoyne. Prognostic Significance of *BCL6* Translocation in Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP. *Blood*, Nov 2008; 112: 3782.
  26. J. Schanz, H. Tuechler, F. Solé, M. Mallo, B. Hildebrandt, M.L. Slovak, K. Ohyashiki, **C. Steidl**, C. Fonatsch, M. Pfeilstoecker, T. Noesslinger, P. Valent, A. Giagounidis, M. Luebbert, R. Stauder, O. Krieger, M.M. Le Beau, J.M. Bennett, P.L. Greenberg, U. Germing, and D. Haase. Cytogenetic Risk Features in MDS-Update and Present State. *Blood*, Nov 2009; 114: 2772.
  27. **C. Steidl**, T. Lee, P. Farinha, A. Telenius, M. Boyle, S.P. Shah, L. Barclay, J.M. Connors, and R.D. Gascoyne. Gene Expression Profiling of Microdissected Hodgkin Reed Sternberg Cells: Molecular Subtypes and Treatment Outcome Correlations. *Blood*, Nov 2009; 114: 268.
  28. P. Farinha, **C. Steidl**, L.M. Rimsza, K.J. Savage, J.M. Connors, and R.D. Gascoyne. HLA-DR Protein Expression Correlates with Non-Neoplastic T-Cell Infiltration and Predicts Survival in Patients with Primary Mediastinal Large B Cell Lymphoma (PMBCL) Treated with CHOP Chemotherapy. *Blood*, Nov 2009; 114: 133.
  29. K.-J. Cheung, N. Johnson, J. Affleck, T. Severson, **C. Steidl**, S. Ben-Neriah, J. Schein, R. Morin, R. Moore, S.P. Shah, H. Qian, J. Paul, A. Telenius, B. Lai, T. Relander, W.L. Lam, K.J. Savage, J.M. Connors, C. Brown, M. Marra, R.D. Gascoyne, and D.E. Horsman. TNFRSF14 Is Mutated in a Subset of Follicular Lymphoma and Correlated with Inferior Prognosis. *Blood*, Nov 2009; 114: 1919.
  30. A.J. Mungall, A. Chu, R. Chiu, R. Corbett, M.A. Field, S.D. Jackman, K.L. Mungall, K. Wong, M. Boyle, R. Carlsen, S.Y. Chan, R.J.N. Coope, C.A. Hirst, M. Hirst, N. Johnson, M. Krzywinski, D. Lee, J. BingXue Lin, R. Moore, T. Severson, J.T. Simpson, **C. Steidl**, T. Zeng, Y. Zhao, I. Birol, R.A. Holt, S.J. Jones, R.D. Gascoyne, D.E. Horsman, J.M. Connors, J.E. Schein, and M.A. Marra. Base-Pair Resolution of Somatic and Germline-Derived Genome Rearrangement Breakpoints in Follicular Lymphoma. *Blood*, Nov 2009; 114: 439.
  31. N.A. Johnson, J.M. Connors, S. Ben-Neriah, S. Rogic, K.J. Savage, **C. Steidl**, D.E. Horsman, G.W. Slack, L. Sehn, W.C. Chan, J. Iqbal, P.N. Meyer, G. Lenz, G.W. Wright, L.M. Rimsza, C. Valentino, P. Brunhoeber, T. Grogan, R.M. Brazziel, J. Cook, R.R. Tubbs, D.D. Weisenburger, E. Campo, A. Rosenwald, G. Ott, J. Delabie, E. Jaffe, L.M. Staudt, and R.D. Gascoyne. Concurrent BCL2 and MYC Protein Expression by Immunohistochemistry Determines Clinical Outcome In DLBCL Patients Treated with R-CHOP. *Blood*, Nov 2010; 116: 2005.
  32. J. Schanz, H. Tüchler, F. Sole, M. Mallo, B. Hildebrandt, **C. Steidl**, C. Fonatsch, M. Pfeilstöcker, T. Nösslinger, P. Valent, A. Giagounidis, M. Lübbert, R. Stauder, O. Krieger, M.M. Le Beau, J.M. Bennett, P.L. Greenberg, U. Germing, and Detlef Haase. Prognostic Impact of Monosomy 7 as a Single Anomaly In Primary MDS – Reclassification From Poor to Intermediate Prognosis. *Blood*, Nov 2010;116:1861.
  33. C. Ganster, F. Braulke, K. Shirneshan, F. Solé, M. Mallo, J. Cervera, E. Luno, B. Hildebrandt, **C. Steidl**, C. Fonatsch, M. Pfeilstöcker, T. Nösslinger, P. Valent, A. Giagounidis, C. Aul, M. Lübbert, R. Stauder, O. Krieger, M.M. Le Beau, J.M. Bennett, P.L. Greenberg, U. Germing, D. Haase, and Julie Schanz. Loss of the Y Chromosome in MDS - Age-Related Phenomenon or Clonal Abnormality? *Blood*, Nov 2010;116:4008.
  34. R.D. Gascoyne and **C. Steidl**. The role of the microenvironment in lymphoid cancers. *Annals of Oncology* 22 (suppl. 4):iv47-iv50, 2011.
  35. **C. Steidl**, S.P. Shah, B.W. Woolcock, L. Rui, M. Kawahara, P. Farinha, A. Telenius, S. Ben Neriah, J.M. Connors, R. Siebert, K.J. Savage, E.S. Jaffe, L.M. Staudt, U. Steidl, M.A. Marra, R.D. Gascoyne. Discovery of CIITA fusions in B cell lymphomas by next generation sequencing. *Annals of Oncology*, 22 (suppl 4): iv148-iv152, 2011.

36. R. Kridel, B. Meissner, S. Rogic, M. Boyle, A. Telenius, J. Gunawardana, C. Cochrane, A.J. Yost, D.W. Scott, K. Tan, B. Woolcock, S. Ben-Neriah, S. Opat, L.H. Sehn, J.M. Connors, A.P. Weng, **C. Steidl**, and R.D. Gascoyne. Whole Transcriptome Sequencing Reveals Recurrent *NOTCH1* Mutations in Mantle Cell Lymphoma. *Blood*, Nov 2011; 118: 436 (abstr.).
37. D.W. Scott, F.C. Chan, F. Hong, S. Rogic, K. Tan, B. Meissner, P. Farinha, S.J. Horning, R.I. Fisher, N.L. Bartlett, L.E. Shepherd, J.M. Connors, A.B. de Sousa, B.S. Kahl, L.I. Gordon, **C. Steidl**, and R.D. Gascoyne. A Gene Expression Signature in Diagnostic Formalin Fixed Paraffin Embedded Tissue Predicts Overall Survival in Locally Advanced and Advanced Stage Classical Hodgkin Lymphoma – a Correlative Study From the E2496 Intergroup Trial. *Blood*, Nov 2011; 118: 430.
38. **C. Steidl**, A. Diepstra, T. Lee, P. Farinha, A. Telenius, M. Boyle, S.P. Shah, L. Barclay, A. van den Berg, K.J. Savage, J.M. Connors, and R.D. Gascoyne. CSF1R Expression of Hodgkin Reed Sternberg Cells Is Associated with the Number of Macrophages in the Tumor Microenvironment and Is Correlated with Treatment Outcome. *Blood*, Nov 2011; 118: 427 (abstr.).
39. **C. Steidl**, B. Woolcock, S. Rogic, S. Ben-Neriah, A. Telenius, M. Drake, R. Siebert, and R.D. Gascoyne. Inactivating Gene Alterations of MHC Class II Transactivator *CIITA* Are Recurrent in Primary Mediastinal B Cell Lymphoma and Hodgkin Lymphoma. *Blood*, Nov 2011; 118: 437 (abstr.).
40. Fong Chun Chan, Susana Ben-Neriah, Raymond Lim, Sandy Hu, Sanja Rogic, Nathalie Johnson, Ryan D Morin, Gavin Ha, Jirau Ding, David W. Scott, Laurie H. Sehn, Joseph M. Connors, Marco A. Marra, Randy D. Gascoyne, Sohrab P Shah, and **Christian Steidl**. Large-Scale High Resolution Integration of Copy Number and Gene Expression in DLBCL Reveals Focal and Frequent Deletions in Chromatin Modifying Genes with Outcome Correlation. *Blood (ASH Annual Meeting Abstracts)*, Nov 2012; 120: 295.
41. Laura Barreyro, Britta Will, Boris Bartholdy, Li Zhou, Tihomira I Todorova, Robert Stanley, Susana Ben-Neriah, Cristina Montagna, Samir Parekh, Andrea Pellagatti, Jacqueline Boulwood, Elisabeth Paietta, Rhett P Ketterling, Larry D Cripe, Hugo F Fernandez, Peter L. Greenberg, Jacob M Rowe, Martin S. Tallman, **Christian Steidl**, Constantine S. Mitsiades, Amit Verma, and Ulrich Steidl. Parallel Transcriptional Analysis of Multiple Stem and Progenitor Populations Identifies Novel Commonly Dysregulated and Functionally Relevant Targets in AML. *Blood (ASH Annual Meeting Abstracts)*, Nov 2012; 120: 1875.
42. Craig H. Moskowitz, Anas Younes, Sven de Vos, R. Gregory Bociek, Leo I. Gordon, Thomas E. Witzig, Randy D. Gascoyne, Brian West, Keith Nolop, and **Christian Steidl**. CSF1R Inhibition by PLX3397 in Patients with Relapsed or Refractory Hodgkin Lymphoma: Results From a Phase 2 Single Agent Clinical Trial. *Blood (ASH Annual Meeting Abstracts)*, Nov 2012; 120: 1638.
43. Graham W. Slack, **Christian Steidl**, Laurie H. Sehn, and Randy D. Gascoyne. CD30 Expression in Diffuse Large B-Cell Lymphoma. *Blood (ASH Annual Meeting Abstracts)*, Nov 2012; 120: 1558.
44. Ujunwa Cynthia Okoye-Okafor, Boris Bartholdy, Bruce Woolcock, Masahiro Kawahara, Tihomira I Todorova, Randy D. Gascoyne, **Christian Steidl**, and Ulrich Steidl. Identification of a Novel Protein-Coding Gene (TIHL) and Its Functional Relevance in Myeloid Cells. *Blood (ASH Annual Meeting Abstracts)*, Nov 2012; 120: 2333.
45. Barreyro, L., Wang, H.R., Bartholdy, B., Will, B., Todorova, T.I., Narayanagari, S.-R., Pujato, M., Kawahara, M., Woolcock, B.W., Gascoyne, R.D., **Steidl, C.** & Steidl, U. Molecular and Functional Characterization Of The Novel Protein-Coding Gene Tihl (Translocated in Hodgkin's Lymphoma) in Hematopoiesis. *Blood (ASH Annual Meeting Abstracts)*, Dec 2013; **122**, 3680.
46. Ennishi, D., Chan, F.C., Scott, D.W., Hother, C., Meissner, B., Boyle, M., Morin, R.D., Sehn, L.H., Marra, M.A., Connors, J.M., **Steidl, C.** & Gascoyne, R.D. Genetic Alterations In Immune Cell Crosstalk Genes In Diffuse Large B-Cell Lymphoma Predict Survival. *Blood (ASH Annual Meeting Abstracts)*, Dec 2013; **122**, 500.
47. Gunawardana, J., Chan, F.C., Telenius, A., Woolcock, B.W., Kridel, R., Tan, K.L., Ben Neriah, S., Lim, R.S., Rogic, S., Boyle, M., Guiter, C., Leroy, K., Haioun, C., Rimsza, L.M., Gaulard, P., Savage, K.J., Connors, J.M., Marra, M.A., Shah, S.P., Gascoyne, R.D. & **Steidl, C.** Protein Tyrosine Phosphatase Type-1 (PTPN1) Is Frequently Mutated In Primary Mediastinal B Cell Lymphoma and Hodgkin Lymphoma. *Blood (ASH Annual Meeting Abstracts)*, Dec 2013; **122**, 242.
48. Zhang, C., **Steidl, C.**, Gascoyne, R.D. & Weng, A.P. Predicting Cell Of Origin In Diffuse Large B-Cell Lymphoma By High Dimensional Flow Cytometry. *Blood (ASH Annual Meeting Abstracts)*, Dec 2013; **122**, 4301.
49. Twa, D.D.W., Chan, F.C., Ben-Neriah, S., Woolcock, B.W., Tan, K.L., Slack, G.W., Gunawardana, J., Lim, R.S., McPherson, A.W., Kridel, R., Telenius, A., Scott, D.W., Savage, K.J., Shah, S.P., Gascoyne, R.D. &

- Steidl, C.** Genomic Rearrangements Involving Programmed Death Ligands Are Recurrent In Primary Mediastinal Large B-Cell Lymphoma. *Blood* (ASH Annual Meeting Abstracts), Dec 2013; **122**, 635.
50. Chan FC, Mottok A, Gerrie AS, Power MM, Savage KJ, Connors JM, Gascoyne RD, Shah SP, Scott DW, **Steidl C.** Analysis of Relapse Biopsies in Classical Hodgkin Lymphoma Reveals Correlations with Outcome after Autologous Stem Cell Transplantation. *Blood* (ASH Annual Meeting Abstracts), Dec 2014; **124**(21),136.
  51. Savage KJ, Sehn LH, Villa D, Kansara RR, Mottok A, Ennishi D, Ben-Neriah S, Kridel R, **Steidl C**, Tan KL, Johnson N, Slack GW, Connors JM, Farinha P, Scott DW, Gascoyne RD. The Impact of Concurrent MYC BCL2 Protein Expression on the Risk of Secondary Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma (DLBCL). *Blood* (ASH Annual Meeting Abstracts), Dec 2014; **124**(21),495.
  52. Ennishi D, Hoffer C, Shulha H, Mottok A, Farinha P, Chan FC, Meissner B, Boyle M, Ben-Neriah S, Morin RD, Marra MA, Savage KJ, Sehn LH, Connors JM, **Steidl C**, Scott DW, Gascoyne RD. Clinical Significance of Genetic Aberrations in Diffuse Large B Cell Lymphoma. *Blood* (ASH Annual Meeting Abstracts), Dec 2014; **124**(21),703.
  53. Kusakabe M, Simkin G, Meskas J, Zhang C, Ennishi D, Boyle M, Scott DW, **Steidl C**, Gascoyne RD, Brinkman RR, Weng AP. Single Cell Mass Cytometry for Phenotypic Analysis of Diffuse Large B-Cell Lymphoma. *Blood* (ASH Annual Meeting Abstracts), Dec 2014; **124**(21),2976.
  54. Mottok A, Woolcock BW, Chan FC, Telenius A, Chavez EA, Boyle M, Ben-Neriah S, Rimsza LM, Siebert R, Gascoyne RD, **Steidl C.** Genetic Alterations of the MHC Class II Transactivator CIITA Are Frequent in Primary Mediastinal Large B-Cell Lymphoma and Associated with Diminished MHC Class II Expression. *Blood* (ASH Annual Meeting Abstracts), Dec 2014; **124**(21),3040.
  55. Wang C, Iqbal J, Zhang W, McKeithan T, Rosenwald A, Gascoyne RD, **Steidl C**, Bouska A, Muhammad Z, Jiang B, Rohr J, Cannon A, Fu K, Weisenburger DD, Greiner TC, Smith LM, Dybkaer K, Ott G, Nakamura S, Seto M, Berger F, Rogan EG, Staudt LM, Vose JM, Chan WC. IDH2R172 Mutations Define a Unique Subgroup of Patients in Angioimmunoblastic T-Cell Lymphoma. *Blood* (ASH Annual Meeting Abstracts), Dec 2014; **124**(21),3580.
  56. **Steidl C.** The Role of the Tumor Microenvironment in Lymphoid Malignancies. *Blood* (ASH Annual Meeting Abstracts), Dec 2015; **126**(23), SCI-46.
  57. Haggood G, Mottok A, Slack GW, Gascoyne RD, **Steidl C**, Savage KJ, Weng AP. Flow Cytometric Characterization of 129 cases of peripheral T Cell Lymphoma not otherwise specified (PTCL NOS) and Angioimmunoblastic T Cell Lymphoma (AITL). *Blood* (ASH Annual Meeting Abstracts), Dec 2015; **126**(23), 2667.
  58. Ennishi D, Mottok A, Savage KJ, Ben-Neriah S, Shulha H, Farinha P, Chan FC, Meissner B, Boyle M, Hother CE, Kridel R, Morin R, Marra MA, Sehn LH, **Steidl C**, Connors JM, Scott DW, Gascoyne RD. Comprehensive MYC and BCL2 genetic profiling in de novo diffuse large B-cell lymphoma demonstrates clinically relevant genetic alterations according to cell of origin subtype. *Blood* (ASH Annual Meeting Abstracts), Dec 2015; **126**(23),109.
  59. Kusakabe M, Wang X, Simkin G, Meskas J, Zhang C, Ennishi D, Kridel R, Boyle M, Chavez E, Hung S, Scott DW, **Steidl C**, Gascoyne R, Brinkman RR, Weng AP. Mass cytometry based classification of inter- and intra-tumoral heterogeneity in diffuse large B-cell lymphoma. *Blood* (ASH Annual Meeting Abstracts), Dec 2015; **126**(23), 3908.
  60. Ennishi D, Mottok A, Shulha H, Farinha P, Chan FC, Meissner B, Boyle M, Ben-Neriah S, Hother CE, Kridel R, Morin R, Marra MA, Savage KJ, Sehn LH, Connors JM, **Steidl C**, Scott DW, Gascoyne RD. Genetic alternations of Gα13 signaling pathway with BCL2 over-expression confers lymphoma dissemination and inferior outcome in germinal cancer B cell diffuse large B cell lymphoma. *Blood* (ASH Annual Meeting Abstracts), Dec 2015; **126**(23), 111.
  61. Mottok A, Johnston RL, Chan FC, Scott DW, Friedman DL, Schwartz C, Kelly KM, Horton TM, **Steidl C.** Prediction of primary treatment outcome using gene expression profiling of pre-treatment biopsies obtained from childhood and adolescent Hodgkin lymphoma patients. *Blood* (ASH Annual Meeting Abstracts), Dec 2015; **126**(23), 175.
  62. Giambra V, Lam SH, Belmonte M, Gusscott S, Salehi S, Chan FC, Kridel R, Lorzadeh A, Hoofd C, **Steidl C**, Eaves CJ, Hirst M, Weng AP. NOTCH1 induces differential epigenomic patterning and genomic organization in fetal liver- and adult bone marrow-derived hematopoietic progenitors. *Blood* (ASH Annual Meeting Abstracts), Dec 2015; **126**(23), 3637.

(c) *Other*



**2. NON-REFEREED PUBLICATIONS**

- (a) *Journals*
- (b) *Conference Proceedings*
- (c) *Other*

**3. BOOKS**

- (a) *Authored*
- (b) *Edited*
- (c) *Chapters*

1. "Cytogenetic and molecular diagnostics" in MDS and acute myeloid leukemia: a biological and therapeutic continuum. (Editor: Prof. Dr. Michael Luebbert). UNI-MED Verlag AG, Bremen Germany, 2007
2. Engert, A., Horning, S.J., Steidl, C. & Gascoyne, R.D. What Will We Learn from Genomics and Proteomics in Hodgkin Lymphoma? in *Hodgkin Lymphoma*, Vol. 0 357-365 (Springer Berlin Heidelberg) 2010.
3. "Cytogenetics of MDS" in The Myelodysplastic Syndromes. (Editor: Varkonyi, Judit). 1<sup>st</sup> Edition, 2011, Springer, Germany, ISBN 978-94-007-0439-8
4. Steidl, C. & Gascoyne, R.D. What Will We Learn from Genomics and Proteomics in Hodgkin Lymphoma? in *Hodgkin Lymphoma – A comprehensive Overview*, (Editors: Engert, A., Younes), pages 79-92 (Springer Berlin Heidelberg). 2015.
5. "Microenvironment-related biomarkers and novel targets in Hodgkin lymphoma"  
Catherine Diefenbach and Christian Steidl. In: *Hodgkin And Non-Hodgkin Lymphomas Seen Through Their Microenvironment: Impact on Diagnosis, Prognosis and Innovative Therapy (Volume 2)*. (Future Medicine Ltd) 2015. Pages 20-34. eBook ISBN: 978-1-78084-582-1

**4. PATENTS**

1. CIITA biomarker for lymphoma classification and prognosis, US Provisional application filed 2011 (invention # 09-038)
2. Gene expression and overall survival in advanced stage classic Hodgkin lymphoma. US Provisional Patent Application # 61569116 (Priority date: December 9, 2011)
3. Identification and use of new tumor-promoting gene in hematological malignancies. US Patent Application No., 14/442,906, PCT International Patent Application No. PCT/US2013/70227 (November 15, 2013)

**5. SPECIAL COPYRIGHTS****6. ARTISTIC WORKS, PERFORMANCES, DESIGNS****7. OTHER WORKS****8. WORK SUBMITTED (including publisher and date of submission)**

9. **WORK IN PROGRESS** (including degree of completion)